aTyr Pharma, Inc. (ATYR)

Market Cap	76.48M
Revenue (ttm)	190,000
Net Income (ttm)	-75.12M
Shares Out	97.99M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	977,280
Open	0.7708
Previous Close	0.7652
Day's Range	0.7578 - 0.7967
52-Week Range	0.6400 - 7.2900
Beta	0.57
Analysts	Buy
Price Target	8.75 (+1,021.08%)
Earnings Date	Nov 6, 2025

About ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ATYR
• Website: https://atyrpharma.com

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ATYR stock is "Buy." The 12-month stock price target is $8.75, which is an increase of 1,021.08% from the latest price.

Price Target

$8.75

(1,021.08% upside)

Analyst Consensus: Buy